TICKERNERD
Menu
ATNMATNMHealthcare · Biotechnology

ATNM Stock Forecast: Actinium Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$1.60
+15.94% on the day

The 4 Wall Street analysts covering Actinium Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +150.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 21 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$43.4M
Ticker Nerd rank
76/ 100
Median analyst target
$4.00
Analysts covering
4
Revenue$35.0M
Operating income$27.6M
Net income$27.9M
Free cash flow−$5.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+50.9%
1M
+36.8%
YTD
+17.6%
1Y
+11.1%
From 52W high
−5.3%
From 52W low
+113.6%
$0.75
$1.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATNM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Actinium Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
76/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
93
Growth
85
Quality
85
Size
82
Volatility
70
Issuance
45
Momentum
42
Revisions
40
Accruals
31

Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (31): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ATNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26ATNMHigh $5.00Median $4.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $2.00Median $4.00High $5.00

The green dot is the last close — the median target sits +150.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026Stephens & Co.ReiteratesOverweight—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
12 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2024Stephens & Co.ReiteratesOverweight—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024HC Wainwright & Co.MaintainsBuy—
6 Aug 2024Maxim GroupMaintainsBuy—
26 July 2024HC Wainwright & Co.ReiteratesBuy—
17 June 2024HC Wainwright & Co.ReiteratesBuy—
21 May 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024Stephens & Co.InitiatesOverweight—
2 May 2024HC Wainwright & Co.ReiteratesBuy—
30 Apr 2024Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ATNM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

ATNM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Actinium Pharmaceuticals, Inc. returned +11.1% against +15.6% for the S&P 500, dividends included.

ATNM vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26ATNMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Actinium Pharmaceuticals, Inc. (ATNM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.8×

Cheaper than 67% of US stocks

Price / sales
1.2×

Cheaper than 63% of US stocks

Price / book
1.4×

Cheaper than 54% of US stocks

EV / EBITDA
0.8×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
78.8%

Higher than 99% of US stocks

Net margin
32.2%

Higher than 91% of US stocks

Returns & dividend
Return on equity
45.9%

Higher than 92% of US stocks

Return on assets
11.6%

Higher than 94% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Actinium Pharmaceuticals, Inc. (ATNM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Actinium Pharmaceuticals, Inc. has a market value of $43.4M and an enterprise value of $8.3M.

  • Revenue in the twelve months to 30 June 2026: $35.1M.

  • Net income over the same four quarters: $11.3M, a 32.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$23.2M.

  • Shares outstanding: 31.4M.

  • Trailing P/E: 3.8×; forward P/E: −2.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Actinium Pharmaceuticals, Inc. employs 27 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

ATNM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATNMActinium Pharmaceuticals, Inc.$43.4M76
ACETAdicet Bio, Inc.$43.0M37
INMBINmune Bio, Inc.$42.8M49
ELTXElicio Therapeutics, Inc.$43.9M36
KLRSKalaris Therapeutics, Inc.$42.3M23
ANVSAnnovis Bio, Inc.$42.3M28
SERSerina Therapeutics, Inc.$45.0M19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Actinium Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATNM news & analysis

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

PRNewsWire · 20 Oct 2026positive

Actinium reported initial Phase 1 results for ATNM-400 in mCRPC at EANM 2026. In the first three-patient cohort at 1.0 µCi/kg, no dose-limiting toxicities, xerostomia, or Grade 3/4 hematologic adverse events were observed; HER3-targeted imaging showed tumor uptake and retention, and the study advanced to 1.5 µCi/kg.

Why it matters — The update provides early safety and tumor-imaging findings for ATNM-400, a first-in-human Actinium-225 radiotherapy approach targeting HER3 in prostate cancer.

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

PRNewsWire · 20 Oct 2026positive

Actinium Pharmaceuticals reported preclinical ATNM-400 results across lung, colorectal and ovarian cancer models at EANM 2026. The company said the studies showed activity across several lung cancer drivers, increased tumor growth inhibition when combined with standard colorectal treatment, and activity in ovarian cancer models, including after bevacizumab failure.

Why it matters — The findings broaden the preclinical evidence for ATNM-400 beyond prostate cancer and may interest investors tracking its potential development across additional tumor types.

Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026

PRNewsWire · 19 Oct 2026positive

Actinium Pharmaceuticals said it will present early data from the ongoing Phase 1 ATNM-400 study in metastatic castration-resistant prostate cancer and preclinical findings in KRAS- and ALK-driven non-small cell lung cancer at EANM 2026. The company describes ATNM-400 as a HER3-targeted alpha radiotherapy approach being explored across solid tumors.

Why it matters — The presentations provide clinical and preclinical updates on ATNM-400 and its potential application beyond prostate cancer.

Actinium Pharmaceuticals Announces Inducement Grants to New Employees

PRNewsWire · 16 Oct 2026neutral

Actinium Pharmaceuticals announced inducement equity awards for newly appointed Chief Financial Officer Matt David, M.D., and newly appointed Senior Vice President of Business Development Sean Maenpaa.

Why it matters — The awards relate to two newly appointed senior executives and may be relevant to shareholders tracking the company’s leadership and compensation.

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

PRNewsWire · 16 Oct 2026positive

Actinium Pharmaceuticals announced three presentations at EANM 2026 featuring preclinical ATNM-400 data across NSCLC, colorectal and ovarian cancer models. The findings include activity in KRAS- and ALK-driven NSCLC, potential to enhance standard-of-care colorectal treatments, and durable activity in ovarian models, including treatment-resistant models.

Why it matters — The presentations add preclinical evidence for ATNM-400's potential across several solid tumor indications and as monotherapy or in combination with existing treatments.

FAQ

Frequently asked questions about ATNM stock

What is the ATNM stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Actinium Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATNM stock a buy right now?

Of the 4 analysts covering Actinium Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actinium Pharmaceuticals, Inc. 76 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATNM?

As at 21 Oct 2026, Actinium Pharmaceuticals, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).

Will ATNM stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +150.0% from the last close, and Ticker Nerd's factor model ranks Actinium Pharmaceuticals, Inc. 76 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATNM stock forecast for 2030?

No analyst covering Actinium Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has ATNM stock performed over the past year?

Actinium Pharmaceuticals, Inc. returned +11.1% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Actinium Pharmaceuticals, Inc. do?

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer.

What is the latest news on ATNM?

The most recent item we track (PRNewsWire, 20 Oct 2026): "Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer". Actinium reported initial Phase 1 results for ATNM-400 in mCRPC at EANM 2026. In the first three-patient cohort at 1.0 µCi/kg, no dose-limiting toxicities, xerostomia, or Grade 3/4 hematologic adverse events were observed; HER3-targeted imaging showed tumor uptake and retention, and the study advanced to 1.5 µCi/kg.

Company

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer. Its current pipeline centers on antibody radiation conjugates and actinium-225-based programs designed to deliver radiation directly to tumor cells while limiting exposure to healthy tissue. The company’s lead product candidate, ATNM-400, is being developed as a multi-indication therapy for solid tumors including prostate cancer, non-small cell lung cancer, and breast cancer. Actinium is also advancing Actimab-A for hematologic malignancies such as acute myeloid leukemia, along with Iomab-ACT for conditioning before gene and cell therapies. Through these programs, Actinium Pharmaceuticals, Inc. plays a specialized role in precision oncology, addressing both solid tumor and blood cancer settings with radiopharmaceutical approaches.

CEO Mr. Sandesh C. Seth M.B.A., M.S. · 27 employees · United States · https://www.actiniumpharma.com